
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- ₹23
- Today's High:
- ₹25.4
- Open Price:
- ₹25.39
- 52W Low:
- ₹20.5
- 52W High:
- ₹51.8
- Prev. Close:
- ₹25.31
- Volume:
- 80446
Company Statistics
- Market Cap.:
- ₹1.02 billion
- Book Value:
- Revenue TTM:
- ₹0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- ₹108.74 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ had its IPO on under the ticker symbol BIBCL.
The company operates in the sector and industry. BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ has a staff strength of 0 employees.
Stock update
Shares of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ opened at ₹25.39 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹23 - ₹25.4, and closed at ₹23.76.
This is a -6.12% slip from the previous day's closing price.
A total volume of 80,446 shares were traded at the close of the day’s session.
In the last one week, shares of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ have slipped by -3.61%.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$'s Key Ratios
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ has a market cap of ₹1.02 billion, indicating a price to book ratio of 1.2363 and a price to sales ratio of 1.5777.
In the last 12-months BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$’s revenue was ₹0 with a gross profit of ₹108.74 million and an EBITDA of ₹0. The EBITDA ratio measures BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q1, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$’s profitability.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ stock is trading at a EV to sales ratio of 2.5154 and a EV to EBITDA ratio of -20.7915. Its price to sales ratio in the trailing 12-months stood at 1.5777.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.86 billion
- Total Liabilities
- ₹914.41 million
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ ended 2025 with ₹1.86 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.86 billion while shareholder equity stood at ₹877.97 million.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ ended 2025 with ₹0 in deferred long-term liabilities, ₹914.41 million in other current liabilities, in common stock, ₹-666293000.00 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹12.86 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$’s total current assets stands at ₹330.63 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹138.76 million compared to accounts payable of ₹4.82 million and inventory worth ₹14.29 million.
In 2025, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ paid ₹0 in dividends in 2025.
Other key metrics
- Current Trading Price
- ₹23.76
- 52-Week High
- ₹51.8
- 52-Week Low
- ₹20.5
- Analyst Target Price
- ₹
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ stock is currently trading at ₹23.76 per share. It touched a 52-week high of ₹51.8 and a 52-week low of ₹51.8. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹23.04 and 200-day moving average was ₹25.16 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.